Mark Verrill

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Sandra M. Swain, Michael S. Ewer, Giuseppe Viale et al. · Annals of Oncology · 2017 · 247 citations · Full text

Medicine, Oncology, Pharmacology +17

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

Anna Jones, Malcolm Barlow, Peter Barrett‐Lee et al. · British Journal of Cancer · 2009 · 216 citations · Full text

Medicine, Cardiology, Oncology +17

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

Peter Barrett‐Lee, Lindsay Johnson, David Cameron et al. · The Lancet · 2009 · 189 citations · Full text

Medicine, Oncology, Pharmacology +13

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

Johanne Bray, J Sludden, Martin J. Griffin et al. · British Journal of Cancer · 2010 · 181 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma

Andy Hughes, Paula Calvert, Ashraf Azzabi et al. · Journal of Clinical Oncology · 2002 · 148 citations

Medicine, Oncology, Pharmacology +16